Related Experiment Videos
[Multiple endocrine neoplasia syndromes. Type 2].
Linas Juodele1, Elona Juozaityte, Algimantas Zindzius
1Clinic of Surgery, Kaunas University of Medicine, Kaunas, Lithuania. juodele@hotmail.com
Medicina (Kaunas, Lithuania)
|May 3, 2005
Summary
Multiple endocrine neoplasia syndrome type 2 (MEN 2) involves rare, inherited conditions causing medullary thyroid carcinoma and other endocrine tumors. Genetic testing aids diagnosis, prognosis, and preventive care for affected families.
Area of Science:
- Endocrinology
- Genetics
- Oncology
Background:
- Multiple endocrine neoplasia syndrome type 2 (MEN 2) comprises rare, autosomal dominant inherited disorders.
- MEN 2 links medullary thyroid carcinoma with other endocrine tumors and endocrinopathies, including MEN 2A, MEN 2B, and familial medullary thyroid carcinoma.
- The genetic cause, germline mutations in the c-ret protooncogene, and pathogenesis are understood.
Purpose of the Study:
- To review the latest data on MEN 2.
- To discuss pathogenesis, diagnostics, patient observation, prophylaxis, and treatment strategies.
- To highlight the role of genetic research in clinical practice.
Main Methods:
- Literature review of recent data on MEN 2.
- Analysis of genotype-phenotype correlations.
- Discussion of genetic screening and its impact on patient management.
Main Results:
- Genetic research enables precise diagnosis of MEN 2 and its subtypes.
- Genotype-phenotype links aid in prognostication and tailored patient observation.
- Genetic screening facilitates early diagnosis, prophylaxis, and improved life prognosis through timely treatment.
Conclusions:
- Genetic advancements have revolutionized MEN 2 management.
- Personalized approaches based on genetic diagnosis improve outcomes.
- Early detection and prophylaxis are crucial for managing MEN 2 and preventing malignant tumors.